Victory Capital Management’s Oragenics OGEN Stock Holding History

Victory Capital Management’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7	Closed	-$1.35K	–	2663
2022 Q4	$1.35K	Hold	7	–	–	﹤0.01%	2584
2022 Q3	$3K	Sell	7 -1	-13%	-$584	﹤0.01%	2688
2022 Q2	$5K	Hold	8	–	–	﹤0.01%	2678
2022 Q1	$5K	Hold	8	–	–	﹤0.01%	2703
2021 Q4	$7K	Sell	8 -1	-11%	-$1.01K	﹤0.01%	2747
2021 Q3	$10K	Hold	9	–	–	﹤0.01%	2759
2021 Q2	$12K	Hold	9	–	–	﹤0.01%	2725
2021 Q1	$15K	Buy	9 +1	+13%	+$1.82K	﹤0.01%	2728
2020 Q4	$6K	Buy	+8	New	+$7.04K	﹤0.01%	2528
2020 Q2	–	Sell	-4	Closed	-$4K	–	3026
2020 Q1	$4K	Buy	+4	New	+$3.84K	﹤0.01%	3363
2019 Q4	–	Sell	-4	Closed	-$4K	–	3059
2019 Q3	$4K	Buy	+4	New	+$3.34K	﹤0.01%	3511

Other funds holding OGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

WWM

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

Victory Capital Management's OGEN Position: Q1 2023 in Review

Victory Capital Management sold out of Oragenics (OGEN) in Q1 2023, closing a stake of 7 shares — an estimated $1.35K sold.

Victory Capital Management first reported a position in OGEN in Q3 2019 and held it in 11 quarters. The position peaked at $15K in Q1 2021. 10 funds tracked by Wall St. Rank hold OGEN as of Q1 2023.

Victory Capital Management reported no remaining Oragenics position as of Q1 2023 after selling out during the quarter.
Victory Capital Management sold 7 Oragenics shares in Q1 2023, an estimated $1.35K.
Victory Capital Management first reported a position in Oragenics in Q3 2019 and held it in 11 quarters.
Victory Capital Management's Oragenics position peaked at $15K in Q1 2021.
10 funds tracked by Wall St. Rank held Oragenics as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.